Latest Breaking News On - Hybrid congress - Page 1 : vimarsana.com

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 Adaptive.

Spain
Madrid
Chicago
Illinois
United-states
University-of-chicago
American
Ciltacabtagene-autoleucel
Susan-bobulsky
Lisocabtagene-maraleucel
Obecabtagene-autoleucel
Brexucabtagene-autoleucel-brexu

Adaptive Biotechnologies Announces Data Supporting the

Adaptive Biotechnologies Announces Data Supporting the
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Madrid
Spain
University-of-chicago
Illinois
United-states
Chicago
American
Idecabtagene-vicleucel-ide
Erica-jones
Susan-bobulsky
Vendexv-pomalidomide
Obecabtagene-autoleucel

Samsung Bioepis to Present Post-hoc Analysis of Phase 3

Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May .

Spain
Madrid
Eculizumab-biosimilar
Younsoo-kim
Samsung-bioepis
Jihyun-han
Paola-russo
Hyejin-kim
Hus-laboratory-monitoring
Lifecycle-safety-team-leader-at-samsung-bioepis
Linkedin
European-hematology-association

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Cambridge
Cambridgeshire
United-kingdom
Becker-hewes
Mastocytosis-adv
Twitter
European-hematology-association
Blueprint-medicines-corporation
European-academy-of-allergy
Prnewswire-blueprint-medicines-corporation-nasdaq
Linkedin
European-commission

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Spain
Ying-qian
Jiangxi
China
Madrid
Tianjin
Texas
United-states
Shanghai
Wuhan
Hubei
Norway